Roth Capital reaffirmed their buy rating on shares of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) in a research note issued to investors on Wednesday morning. The firm currently has a $6.00 price objective on the stock.
Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.8275 on Wednesday. The company’s market capitalization is $78.69 million. Pieris Pharmaceuticals has a 52 week low of $1.26 and a 52 week high of $3.08. The firm has a 50-day moving average of $1.64 and a 200-day moving average of $1.79.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. The firm had revenue of $1.07 million for the quarter. Pieris Pharmaceuticals had a negative net margin of 346.01% and a negative return on equity of 52.21%. Analysts anticipate that Pieris Pharmaceuticals will post ($0.55) EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of PIRS. Sabby Management LLC raised its position in Pieris Pharmaceuticals by 823.4% in the second quarter. Sabby Management LLC now owns 1,615,992 shares of the company’s stock worth $2,602,000 after buying an additional 1,440,992 shares during the last quarter. Lombard Odier Asset Management USA Corp raised its position in Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock worth $5,099,000 after buying an additional 533,965 shares during the last quarter. BVF Inc. IL acquired a new position in Pieris Pharmaceuticals during the second quarter worth $389,000. Frontier Wealth Management LLC acquired a new position in Pieris Pharmaceuticals during the second quarter worth $137,000. Finally, BlackRock Fund Advisors acquired a new position in Pieris Pharmaceuticals during the second quarter worth $113,000. Hedge funds and other institutional investors own 45.79% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.